



## Cucurbitane-type triterpenoids from the stems and leaves of *Momordica charantia*



Gao-Ting Zhao<sup>a</sup>, Jie-Qing Liu<sup>b</sup>, Yuan-Yuan Deng<sup>b,c</sup>, Hai-Zhou Li<sup>a</sup>, Jian-Chao Chen<sup>b</sup>, Zhi-Run Zhang<sup>b</sup>, Lin Zhou<sup>b</sup>, Ming-Hua Qiu<sup>b,c,\*</sup>

<sup>a</sup> Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, Yunnan, People's Republic of China

<sup>b</sup> State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, Yunnan, People's Republic of China

<sup>c</sup> University of Chinese Academy of Science, Beijing 100049, People's Republic of China

### ARTICLE INFO

#### Article history:

Received 20 January 2014

Accepted in revised form 26 February 2014

Available online 14 March 2014

#### Keywords:

*Momordica charantia*

Cucurbitaceae

Cucurbitane-type triterpenoids

Cytotoxicity

### ABSTRACT

Six new cucurbitane-type triterpenoids, karavilagenin F (**1**), karavilosides XII and XIII (**2**, **3**), momordicines VI, VII, and VIII (**4**, **5** and **6**), along with four known ones, 5 $\beta$ ,19-epoxy-25-methoxycucurbita-6,23-diene-3 $\beta$ ,19-diol (**7**), 5 $\beta$ ,19-epoxycucurbita-6, 23-diene-3 $\beta$ ,19,25-triol (**8**), kuguacin R (**9**), and (19R,23E)-5 $\beta$ ,19-epoxy-19-methoxycucurbita-6,23,25-trien-3 $\beta$ -ol (**10**), were isolated from the stems and leaves of *Momordica charantia* L. Their chemical structures were elucidated by extensive 1D NMR and 2D NMR (HSQC, HMBC, COSY, and ROESY), MS experiments, and CD spectrum. Compound **6** showed weak cytotoxicity against five human cancer cells lines with IC<sub>50</sub> values of 14.3–20.5  $\mu$ mol/L.

© 2014 Elsevier B.V. All rights reserved.

## 1. Introduction

*Momordica charantia* L. (Cucurbitaceae), also called “kugua” in Chinese and “bitter gourd” in English, is widely cultivated as a favorable vegetable crop in China, India, Japan and other Asian countries. It has also been extensively used in folk medicine to prevent and treat fever polydipsia, diarrhea, colic and diabetes in China [1]. Many phytochemical researches on the fruits, vines, leaves, stems, and seeds of *M. charantia* have been reported, which cause isolation of many cucurbitane-type triterpenoids [2–4], few of sterols [5], alkaloids and others [6]. Meanwhile, numerous studies have also confirmed different pharmacological activities of crude extracts and partial triterpenoids, such as antidiabetic [7–9], antitumor [10–12], antioxidant [2,13], antiviral [14] and antiobesity [15,16]. In recent years, anti-cancer activities of *M. charantia*, such as mouse skin cancer [10], prostate cancer [11,12], breast cancer

[17], and human bladder carcinoma [18] have been concerning, suggesting that compounds possessing antitumor effects may be present in this species.

Therefore, on the basis of an interest in the isolation and identification of compounds with potent anticancer from *M. charantia*, firstly, we documented the extraction, isolation, purification, and structural elucidation of six new cucurbitane-type triterpenoids (**1–6**) and four known compounds (**7–10**) (Fig. 1) from the stems and leaves of *M. charantia*; subsequently, the inhibitory activities of compounds **3**, **4** and **6** against five human cancer cell lines, HL-60, SMMC-7721, A-549, MCF-7, and SW480 by using the MTT method *in vitro* were also reported.


## 2. Experimental

### 2.1. General experimental procedures

Optical rotations were obtained with a Jasco P-1020 polarimeter. UV spectra were run on a UV 210A spectrophotometer. The CD spectra were recorded on a Chirascan instrument. <sup>1</sup>H and <sup>13</sup>C NMR spectra were measured on Bruker AV-400 and DRX-500 instruments (Bruker, Zurich,

\* Corresponding author at: State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, Yunnan, People's Republic of China. Tel.: +86 871 65223257; fax: +86 871 65223255.

E-mail address: [mhchiu@mail.kib.ac.cn](mailto:mhchiu@mail.kib.ac.cn) (M.-H. Qiu).



**Fig. 1.** The structures of 1–10.

Switzerland) with  $\text{Me}_4\text{Si}$  (TMS) as internal standard. ESIMS and HREIMS data were recorded on an API QSTAR Pulsar spectrometer and infrared spectra were recorded on a Bruker Tensor-27 instrument by using KBr pellets. Semi-preparative HPLC was performed on an Agilent 1100 liquid chromatograph with a ZORBAX SB-C18 (5  $\mu\text{m}$ ,  $9.4 \times 250$  mm) column. TLC was performed on precoated TLC plates (200–250  $\mu\text{m}$  thickness, F254 Silica gel 60, Qingdao Marine Chemical,

Inc.) with compounds visualized by spraying the dried plates with 10% aqueous  $\text{H}_2\text{SO}_4$  followed by heating until dryness. Silica gel (200–300 mesh, Qingdao Marine Chemical, Inc., Lichroprep RP-18 (40–63  $\mu\text{m}$ , Merck) was used for column chromatography. Methanol, dichloromethane, ethyl acetate, acetone, petroleum ether, n-butanol and methyl cyanides were purchased from Tianjin Chemical Reagents Co. (Tianjin, China).

## 2.2. Plant material

The mature stems and leaves of *M. charantia* were collected in Guangzhou, in June 2010. The plant material was identified by Prof. Dai Hao-fu, and a voucher specimen (no. KIB 2010-6) was deposited at the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy Sciences.

## 2.3. Extraction and isolation

Dried stems and leaves 9 kg of *M. charantia* were cut into small pieces and then extracted three times with methanol under reflux. The solvent was concentrated under vacuum to obtain the MeOH extract 550 g, which was suspended in H<sub>2</sub>O and extracted with petroleum ether, CHCl<sub>3</sub> and n-BuOH, respectively. The CHCl<sub>3</sub> and n-BuOH mixed extract 350 g was chromatographed on silica gel (CHCl<sub>3</sub>/MeOH, 80:1, 20:1, 0:1) to afford the CHCl<sub>3</sub>/MeOH (20:1) fraction 110 g, which was subjected to RP-18 column, eluted with MeOH/H<sub>2</sub>O (45:55, 50:50, 60:40, 65:35, 70:30, 80:20, 100:0) to give five fractions (Fr.1–Fr.5). Fr.4 (23.1 g) was subjected to silica gel CC and eluted with a gradient system of CHCl<sub>3</sub>/MeOH (100:1, 50:1, 30:1, 5:1) to yield ten subfractions (Fr.4-1–Fr.4-10) by TLC. Fr.4-1 (4 g) was applied to silica gel CC using CHCl<sub>3</sub>/(Me)<sub>2</sub>CO (120:1, 60:1, 40:1) to afford compound **6** (63.3 mg). Fr.4-3 (362.9 mg) was repeatedly isolated by semi-preparative HPLC with 70–80% CNCH<sub>3</sub>/H<sub>2</sub>O (flow rate 3.0 mL/min; UV detector, 205 nm) and P-TLC (petroleum ether-acetone, 4:1) to yield compounds **1** (5.0 mg), **4** (3.5 mg), **5** (2.3 mg), **7** (4.0 mg), **8** (3.0 mg), **9** (3.7 mg), and **10** (6.0 mg). Fr.4-8 (3.5 g) was submitted to repeated chromatography over silica gel (CHCl<sub>3</sub>/MeOH, 50:1 and 5:1) and semi-preparative HPLC (CNCH<sub>3</sub>/H<sub>2</sub>O, 60–70%; flow rate 3.0 mL/min; UV detector, 205 nm) to give compound **3** (t<sub>R</sub> = 16.2 min, 8.5 mg). Fr.4-10 (5.9 g) was isolated by semi-preparative HPLC (CNCH<sub>3</sub>/H<sub>2</sub>O, 50–70%; flow rate 3.0 mL/min; UV detector, 205 nm) to afford compound **2** (t<sub>R</sub> = 21.8 min, 1.8 mg).

**Karavilagenin F (1)**: white amorphous powder; [ $\alpha$ ]<sub>D</sub>24.9 D-60.9° (c 0.22, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ) 202 (3.62) nm; IR (KBr)  $\nu_{max}$  3441, 2925, 2875, 1631, 1465, 1412, 1382, 1272, 1115, 1082 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; ESIMS  $m/z$  525 [M + Na]<sup>+</sup>; HREIMS,  $m/z$  502.3647 (calcd for C<sub>31</sub>H<sub>50</sub>O<sub>5</sub> [M]<sup>+</sup>, 502.3658).

**Karaviloside XII (2)**: white amorphous powder; [ $\alpha$ ]<sub>D</sub>24.9 D-16.5° (c 0.16, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ) 203 (3.09) nm; IR (KBr)  $\nu_{max}$  3441, 2923, 2871, 1725, 1630, 1445, 1382, 1251, 1155, 1080, 1038 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; ESIMS  $m/z$  683 [M + Na]<sup>+</sup>; HREIMS,  $m/z$  at 660.4249 (calcd for C<sub>38</sub>H<sub>60</sub>O<sub>9</sub> [M]<sup>+</sup>, 660.4237).

**Karaviloside XIII (3)**: white amorphous powder; [ $\alpha$ ]<sub>D</sub>25.1 D-11.2° (c 0.14, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ) 203 (3.23) nm; IR (KBr)  $\nu_{max}$  3441, 2926, 2873, 1632, 1448, 1382, 1083, 1034 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; ESIMS  $m/z$  641 [M + Na]<sup>+</sup>; HREIMS,  $m/z$  at 618.4123 (calcd for C<sub>36</sub>H<sub>58</sub>O<sub>8</sub> [M]<sup>+</sup>, 618.4132).

**Momordicine VI (4)**: white amorphous powder; [ $\alpha$ ]<sub>D</sub>24.9 D + 28.1° (c 0.23, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ) 203 (3.71) nm; IR (KBr)  $\nu_{max}$  3440, 2934, 2877, 1710, 1631, 1465, 1449, 1381, 1085 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1

and 2; ESIMS  $m/z$  509 [M + Na]<sup>+</sup>; HREIMS,  $m/z$  at 486.3715 (calcd for C<sub>31</sub>H<sub>50</sub>O<sub>4</sub> [M]<sup>+</sup>, 486.3709).

**Momordicine VII (5)**: white amorphous powder; [ $\alpha$ ]<sub>D</sub>25.0 D + 51.0° (c 0.09, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ) 203 (3.89) nm; IR (KBr)  $\nu_{max}$  3440, 2954, 2933, 2877, 1728, 1629, 1463, 1442, 1382, 1273, 1153, 1075, 1019, 977 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; ESIMS,  $m/z$  at 595 [M + Na]<sup>+</sup>; HREIMS,  $m/z$  at 572.3703 (calcd for C<sub>34</sub>H<sub>52</sub>O<sub>7</sub> [M]<sup>+</sup>, 572.3713).

**Momordicine VIII (6)**: white amorphous powder; [ $\alpha$ ]<sub>D</sub>24.9 D-8.2° (c 0.25, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ) 203 (3.51) nm; IR (KBr)  $\nu_{max}$  3441, 2951, 2924, 2875, 2854, 1733, 1631, 1462, 1442, 1381, 1272, 1153, 1078, 1021, 980 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; ESIMS,  $m/z$  at 609 [M + Na]<sup>+</sup>; HREIMS,  $m/z$  at 586.3862 (calcd for C<sub>35</sub>H<sub>54</sub>O<sub>7</sub> [M]<sup>+</sup>, 586.3870).

## 2.4. The CD spectrum

The CD spectrum was obtained at room temperature in DMSO and step scans were collected at 1 nm/step with an integration time of 1 s over the range 250–600 nm. For the CD standard measurements the chiral vic-diols (compound **1**, 1 mg) was dissolved in DMSO (concentration: 0.6667 mg/mL), and then added in suitable [Mo<sub>2</sub>(OAc)<sub>4</sub>] so that situ formed Mo-complexes of **1** at ligand to metal molar ratios was about 1.0:1.2. Due to the real complex structure as well as the concentration of the chiral complex formed in solution was not known, the CD data are presented as the  $\Delta\epsilon'$  values. These  $\Delta\epsilon'$  values are calculated in the usual way as  $\Delta\epsilon' = \Delta A / c \times d$ , where  $c$  is the molar concentration of the chiral ligand, assuming 100% complexation ( $A$  = absorption;  $d$  = path length of the cell).  $\Delta\epsilon'$  is expressed in [M<sup>-1</sup> × cm<sup>-1</sup>] units.

## 2.5. Cytotoxicity assay

The cytotoxic activities of compounds **3**, **4** and **6** were evaluated against five human cancer cell lines: HL-60, SMMC-7721, A-549, MCF-7, and SW480, which were acquired from ATCC (Manassas, VA, USA) and were cultured in RPMI-1640 or DMEM medium (Hy-clone, Logan, UT, USA) by means of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-zolium (MTS) assay, an analog of MTT. Briefly, cells in RPMI-1640 or DMEM medium supplemented with 10% fetal bovine serum (FBS, Hyclone) were seeded into a 96-well cell culture plate in the presence of various concentrations of test compounds at 37 °C in a 5% CO<sub>2</sub> humidified incubator for 48 h. Reduced MTS crystals were dissolved in DMSO, and the optical density (OD) was measured at 490 nm in a 96-well microtiter plate reader (Bio-Rad 680) to determine cell growth inhibition. Cisplatin (MW 300) and paclitaxel were included as a positive control. The IC<sub>50</sub> value of each compound was calculated by Reed and Muench's method.

## 3. Results and discussion

The methanol extracts of the stems and leaves of *M. charantia* were partitioned into petroleum ether, CHCl<sub>3</sub>, and n-BuOH fractions. The CHCl<sub>3</sub> and n-BuOH mixed extract fraction was repeated subjected to silica gel, RP-18 column

**Table 1**<sup>1</sup>H NMR data (δ) of compounds **1–6** (J in Hz).

Position	1 <sup>b, d</sup>	2 <sup>b, d</sup>	3 <sup>a, d</sup>	4 <sup>b, d</sup>	5 <sup>b, d</sup>	6 <sup>a, c</sup>
<i>Aglycon moiety</i>						
1	1.50 m, 1.69 m	1.38 m, 1.46 m	1.40 m, 1.49 m	1.77 m, 2.10 overlapped	1.57 overlapped, 1.66 m	1.34 overlapped, 1.71 overlapped
2	1.82 m, 1.91 m	1.76 m, 1.85 m	1.80 m, 1.86 m	2.10 overlapped, 1.99 m	1.17 m, 1.86 m	1.34 overlapped, 1.89 m
3	3.58 brs	5.00 brs	3.54 m	3.85 brs	5.02 t	4.80 brs
6	5.65 dd (3.6, 9.6)	6.17 d (9.8)	6.11 d (9.7)	6.31 d (4.2)	6.16 d (3.9)	5.85 d (3.5)
7	6.11 dd (1.8, 9.6)	5.58 dd (3.5, 9.8)	5.58 dd (3.6, 9.7)	4.39 d (5.4)	4.31 d (5.3)	3.96 d (4.3)
8	3.07 brs	2.30 brs	2.25 brs	2.40 s	2.33 s	1.99 brs
10	2.49 dd (5.9, 12.2)	2.29 dd (5.4, 12.3)	2.29 dd (5.5, 12.1)	2.72 m	2.60 dd (4.2, 12.7)	2.50 d (11.7)
11	1.65 m, 1.76 m	1.39 m, 1.67 m	1.33 m, 1.61 m	1.61 m, 2.77 m	1.50 m, 2.68 m	1.54 m, 2.21 m
12	1.64 m	1.57 m	1.53 m, 1.59 m	1.66 m, 1.73 m	1.49 overlapped, 1.56 overlapped	1.22 m, 1.64 m
15	1.23 m	1.17 m, 1.26 m	1.15 m, 1.20 m	1.34 overlapped	1.27 m, 1.32 m	1.34 overlapped
16	1.46 m, 1.96 m	1.50 m, 1.97 m	1.46 m, 1.91 m	1.92 overlapped, 1.34 overlapped	1.29 m, 1.92 m	1.71 overlapped, 1.86 m
17	1.56 dd (8.9, 18.3)	1.50 m	1.46 m	1.50 m	1.49 overlapped	1.45 m
18	0.94 s	0.82 s	0.78 s	0.92 s	0.82 s	0.84 s
19	4.78 s	3.61 d (8.0)	3.51 d (8.4)	10.71 s	10.51 s	9.72 s
		3.73 d (8.0)	3.60 d (8.4)			
20	2.18 m	2.17 m	2.10 m	1.93 overlapped	1.43 m	1.49 m
21	1.13 d (6.3)	1.20 d (6.8)	1.13 d (6.3)	1.10 d (6.4)	0.94 d (6.3)	0.87 d (5.7)
22	1.62 m, 2.06 m	1.24 m, 2.12 m	1.20 m, 2.06 m	1.07 m, 1.87 m	1.83 m, 2.20 m	1.75 m, 2.14 m
23	4.28 dd (5.3, 9.6)	4.98 m	4.88 m	4.15 td (2.8, 9.8)	5.91 m	5.45 dd (6.6, 14.4)
24	4.57 d (5.3)	5.66 d (8.1)	5.64 d (8.7)	5.22 d (8.8)	5.93 m	5.35 d (15.7)
26	5.13 s, 5.48 s	1.70 s	1.66 s	1.75 s	1.53 s	1.21 s
27	2.04 s	1.78 s	1.69 s	1.71 s	1.54 s	1.21 s
28	0.87 s	1.21 s	1.36 s	1.51 s	1.11 s	1.07 s
29	1.40 s	0.95 s	0.88 s	1.20 s	1.24 s	1.13 s
30	0.89 s	0.90 s	0.85 s	0.88 s	0.74 s	0.71 s
19-OMe	3.38 s					
23-OMe				3.29 s		
25-OMe						3.10 s
3-COCH <sub>3</sub>		2.09 s				
1"-OMe					3.68 s	3.69 s
2"					3.59 s, 3.60 s	3.31 s
<i>sugar moiety</i>						
1'		5.02 d (7.8)	5.40 d (7.8)			
2'		4.09 m	4.70 t			
3'		4.30 m	3.97 dd (2.2, 5.4)			
4'		4.28 m	4.22 dd (2.5, 9.3)			
5'		3.94 m	4.40 m			
6'		4.40 dd (5.0, 11.6)	4.33 dd (4.7, 11.0)			
		4.53 dd (2.0, 11.6)	4.45 dd (2.3, 11.0)			

<sup>a</sup> Recorded at 500 MHz.<sup>b</sup> Recorded at 600 MHz.<sup>c</sup> Data were determined in CDCl<sub>3</sub>.<sup>d</sup> Data were determined in C<sub>5</sub>D<sub>5</sub>N.

and semi-preparative HPLC to yield six new cucurbitane-type triterpenoids (**1–6**), in addition to four known ones (**7–10**).

Compound **1** was isolated as a white powder. Its molecular formula,  $C_{31}H_{50}O_5$ , was determined by HREIMS ( $m/z$  502.3647,  $[M]^+$ , calcd 502.3658). The IR spectrum showed characteristic bands of hydroxy group ( $3441\text{ cm}^{-1}$ ) and double bonds ( $1631\text{ cm}^{-1}$ ). The  $^1\text{H}$  and  $^{13}\text{C}$  NMR (Tables 1 and 2) in combination with DEPT and HSQC spectra of **1** showed 31 carbon signals, indicating that it was a cucurbitane-type triterpene skeleton with an methoxyl [ $\delta_{\text{H}}$  3.38 (3H, s),  $\delta_{\text{C}}$  58.0, q]. In addition, the downfield region in  $^{13}\text{C}$ -DEPT of **1** showed a disubstituted double bond [ $\delta_{\text{C}}$  133.2 (d), 132.1 (d)], an oxygenated quaternary carbon at  $\delta$  87.4

(s), and a hemiacetal signal at  $\delta_{\text{C}}$  112.6 (d) (proton resonance at  $\delta_{\text{H}}$  4.78, s), explicated the typical 6-en, 5, 19-hemiacetal ring. As mentioned above, the  $^{13}\text{C}$ -NMR data of four rings in **1** were similar to those of in (19*R*,23*E*)-5 $\beta$ ,19-epoxy-19-methoxycucurbita-6,23,25-trien- $\beta$ -ol [19] and of the side chain in **1** were virtually identical to those of in (3 $\beta$ ,7 $\beta$ )-3,7,22,23-tetrahydroxycucurbita-5,24-dien-19-al [4]. The OH group was at C-3 was further elucidated by HMBC experiment, in which the cross peak of H<sub>3</sub>-28 ( $\delta_{\text{H}}$  0.87) with C-3 ( $\delta_{\text{C}}$  76.6), C-4 ( $\delta_{\text{C}}$  38.1) and C-5 ( $\delta_{\text{C}}$  87.4) was observed. The presence of a vic-diol system at C-23 and C-24 was indicated by the  $^1\text{H}$ - $^1\text{H}$  COSY coupling between H-23 ( $\delta_{\text{H}}$  4.28) and H-24 ( $\delta_{\text{H}}$  4.57) and was supported by the HMBC correlations

**Table 2**

$^{13}\text{C}$  NMR data ( $\delta$ ) of compounds **1–6**.

Position	1 <sup>b, d</sup>	2 <sup>b, d</sup>	3 <sup>a, d</sup>	4 <sup>b, d</sup>	5 <sup>b, d</sup>	6 <sup>a, c</sup>
<i>Aglycon moiety</i>						
1	18.2 t	19.1 t	18.0 t	22.2 t	22.2 t	21.5 t
2	28.3 t	26.1 t	28.0 t	30.3 t	28.1 t	27.3 t
3	76.6 d	77.3 d	76.3 d	76.1 d	80.3 d	79.3 d
4	38.1 s	38.1 s	37.6 s	42.2 s	40.5 s	39.7 s
5	87.4 s	85.2 s	87.6 s	146.1 s	144.0 s	144.3 s
6	133.2 d	134.1 d	132.4 d	124.7 d	125.2 d	123.1 d
7	132.1 d	130.6 d	131.4 d	66.1 d	65.7 d	65.9 d
8	42.5 d	52.6 d	52.2 d	51.1 d	51.2 d	48.1 d
9	48.9 s	45.7 s	45.6 s	51.0 s	50.8 s	49.4 s
10	41.4 d	40.3 d	39.3 d	37.3 d	36.6 d	36.7 d
11	23.9 t	24.4 t	23.9 t	23.1 t	22.9 t	23.1 t
12	31.4 t	31.6 t	31.2 t	30.0 t	29.7 t	28.8 t
13	45.9 s	46.0 s	45.6 s	46.3 s	46.1 s	45.1 s
14	48.7 s	49.3 s	48.8 s	48.7 s	48.6 s	47.6 s
15	34.1 t	33.8 t	33.4 t	35.3 t	35.2 t	34.4 t
16	28.9 t	28.7 t	28.3 t	28.5 t	26.6 t	25.9 t
17	52.1 d	51.7 d	51.3 d	51.5 d	50.5 d	49.7 d
18	15.3 q	15.4 q	15.0 q	15.4 q	15.4 q	14.7 q
19	112.6 d	80.4 t	79.9 t	208.4 d	208.0 d	207.7 d
20	33.1 d	33.1 d	32.7 d	33.3 d	36.9 d	35.9 d
21	19.3 q	19.7 q	19.4 q	19.5 q	19.3 q	18.6 q
22	39.8 t	44.2 t	43.7 t	43.8 t	39.9 t	39.2 t
23	70.3 d	75.7 d	75.2 d	75.1 d	124.6 d	128.1 d
24	80.4 d	129.5 d	129.3 d	128.3 d	142.2 d	136.7 d
25	148.2 s	132.7 s	132.0 s	135.0 s	70.1 s	74.7 s
26	112.3 t	26.3 q	25.8 q	26.3 q	31.3 q	25.9 q
27	19.7 q	18.7 q	18.2 q	18.6 q	31.3 q	25.6 q
28	24.6 q	20.7 q	21.0 q	26.7 q	27.3 q	26.9 q
29	21.3 q	25.3 q	24.6 q	27.7 q	25.5 q	24.7 q
30	20.4 q	20.4 q	20.2 q	18.6 q	18.4 s	17.7 q
3-COCH <sub>3</sub>		171.4 s				
3-COCH <sub>3</sub>		21.8 q				
19-OMe	58.0 q					
23-OMe				56.0 q		
25-OMe						50.1 q
1"-OMe					52.8 q	52.4 q
1"					168.0 s	166.8 s
2"					42.3 t	41.4 t
3"					166.9 s	165.8 s
<i>Sugar moiety</i>						
1'		104.7 d	101.6 d			
2'		76.1 d	73.2 d			
3'		79.4 d	72.8 d			
4'		72.2 d	69.3 d			
5'		78.8 d	75.7 d			
6'		63.3 t	63.3 t			

<sup>a</sup> Recorded at 125 MHz.

<sup>b</sup> Recorded at 150 MHz.

<sup>c</sup> Data were determined in CDCl<sub>3</sub>.

<sup>d</sup> Data were determined in C<sub>5</sub>D<sub>5</sub>N.

observed from H-23 to C-24 ( $\delta_C$  80.4) and from H-24 to C-26 ( $\delta_C$  112.3) and C-27 ( $\delta_C$  19.7).

Numerous researches recently indicated a simple and unequivocal method which mixed a transition metal chelate reagent dimolybdenum tetraacetate [ $\text{Mo}_2(\text{OAc})_4$ ] and chiral *vic*-diols in DMSO and record the CD spectrum in the 250–600 nm spectral range to determine the absolute configuration of acyclic chiral *vic*-diols [20–24]. The resulting CD spectrum suggested that the absolute configuration of *vic*-diols is correlated the sign of the O–C–C–O torsional angle with the sign of Cotton effects (CEs) occurring in the 300–400 nm spectral range (helicity rule [22], determined the molecular stereostructure of *vic*-diols). According to the rule, a positive (negative) sign of CEs occurring on around 310 and 400 nm is related to a positive (negative) sign of O–C–C–O torsional angle of the diol unit. According to the proposed method, the CD spectrum of *vic*-diols in **1** was acquired (Fig. 2). In the CD spectrum, two positive CD bands at around 300 and 400 nm can be seen and the positive sign of these CD bands corresponds to a positive torsion angle of the O–C–C–O moiety in its preferred antiperiplanar conformation, as presented in the bottom of Fig. 2. Therefore, the configuration at C-23 and C-24 was deduced as *S*, *S*.

The stereochemistry at C-19 of **1** was deduced to be *R* by comparing the  $^{13}\text{C}$ -NMR chemical shifts of C-8 ( $\delta_C$  42.5), C-10 ( $\delta_C$  41.4), and C-19 ( $\delta_C$  112.6) with those of (19*R*,23*E*)-5 $\beta$ ,19-epoxy-19-methoxycucurbita-6,23,25-trien- $\beta$ -ol [19] [C-8 ( $\delta_C$  41.7), C-10 ( $\delta_C$  40.5), and C-19 ( $\delta_C$  112.1)] and (19*S*,23*E*)-5 $\beta$ ,19-epoxy-19-methoxycucurbita-6,23-diene-3 $\beta$ ,25-diol [25] [C-8 ( $\delta_C$  49.8), C-10 ( $\delta_C$  37.9), and C-19 ( $\delta_C$  114.7)]. The *R* configuration of C-19 was also supported by the ROE correlation between H-1 $\beta$  and H-19 [10]. The orientation of 3 $\beta$ -OH was also testified by ROESY experiment, following the ROE correlation of H-3 and H<sub>3</sub>-28. Thus, compound **1** was concluded




Fig. 2. CD spectra of *in situ* formed Mo-complexes of *vic*-diol **1** recorded in DMSO and preferred conformation of the diols in the chiral Mo-complexes (bottom).

to be (19*R*,23*S*,24*S*)-5 $\beta$ ,19-epoxy-19-methoxycucurbita-6,25-dien-3 $\beta$ ,23,24-triol (karavilagenin F).

Compound **2**, a white powder, has a molecular formula of  $\text{C}_{38}\text{H}_{60}\text{O}_9$  as determined by the positive HREIMS ion at  $m/z$   $[\text{M}]^+$  (calcd 660.4237). The IR spectrum displayed absorptions at 3441, 1725, and 1630  $\text{cm}^{-1}$ , suggesting the presence of hydroxy group, ester, and double bonds, respectively. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of **2** showed 38 carbon signals, which were attributed to a triterpene skeleton, a glucosyl moiety [ $\delta_C$  104.7 (d), 76.1 (d), 79.4 (d), 72.2 (d), 78.8 (d), 63.3 (t);  $\delta_H$  5.02 (1H, d,  $J = 7.8$  Hz), H-1'] [10,26], and an acetyl group [ $\delta_H$  2.09 (3H, s),  $\delta_C$  21.8 (q), 171.4 (s)]. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of triterpene aglycone were closely similar to those of karavilagenin E [27]. By detailed analysis of its HSQC and HMBC spectra, a proton signal at  $\delta$  5.00 attributing to H-3 correlated with the acetyl carbon at  $\delta_C$  171.4 in the HMBC spectrum, which suggested that the acetyl group was located at C-3. Meanwhile, conjugation at C-23 of the aglycon with the glucosyl moiety was supported from the HMBC experiment, which showed cross correlations between H-23 ( $\delta_H$  4.98) and C-1' ( $\delta_C$  104.7) of the glucose moiety, C-20 ( $\delta_C$  33.1), C-22 ( $\delta_C$  44.2), C-24 ( $\delta_C$  129.5), C-25 ( $\delta_C$  132.7), and between H-1' ( $\delta_H$  5.02) and C-23 ( $\delta_C$  75.7). The configuration of the glucosyl moiety was further determined to be  $\beta$  based on the coupling constant ( $\delta_H$  5.02 d,  $J = 7.8$  Hz) of the anomeric proton. The 3 $\beta$ -OAc and 5 $\beta$ ,19-oxygen bridge were explicated by ROESY correlations of H-3/H<sub>3</sub>-28, of H-8/H<sub>3</sub>-18 and of H-8/H<sub>2</sub>-19. Consequently, compound **2** was assumed to be 5 $\beta$ ,19-epoxycucurbita-6,24-dien-3 $\beta$ -acetoxyl-23-O- $\beta$ -D-glucopyranoside (karaviloside XII).

Compound **3**, a white powder, has an elemental composition of  $\text{C}_{36}\text{H}_{58}\text{O}_8$  (calcd 618.4132), based on the result of HREIMS at  $m/z$  (618.4123)  $[\text{M}]^+$ . Its IR spectrum showed the presence of hydroxy group (3441  $\text{cm}^{-1}$ ) and double bands (1632  $\text{cm}^{-1}$ ). The 1D-NMR spectrum resolved 36 carbon signals due to a triterpene skeleton and a  $\beta$ -D-allopyranosyl moiety [ $\delta_C$  101.6 (d), 73.2 (d), 72.8 (d), 69.3 (d), 75.7 (d), 63.3 (t);  $\delta_H$  5.40 (1H, d,  $J = 7.8$  Hz), H-1'] [7,10]. Comparison of the  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of **3** with those of **2** showed similarities except that the  $\beta$ -D-glucopyranosyl moiety at C-23 and the acetoxyl group at C-3 in **2** were replaced by a  $\beta$ -D-allopyranosyl functionality and a hydroxy group in **3**, respectively. Above deduction were further determined by following  $^1\text{H}$ - $^1\text{H}$  COSY and HMBC correlations: 1) the  $^1\text{H}$ - $^1\text{H}$  COSY correlation of olefinic proton signal at  $\delta$  5.64 attributing to H-24 with H<sub>3</sub>-26 ( $\delta_H$  1.66) suggested that the trisubstituted double bond was located C-23; 2) the HMBC correlations from H-23 ( $\delta_H$  4.88) to C-1' ( $\delta_C$  101.6), C-20 ( $\delta_C$  32.7), C-22 ( $\delta_C$  43.7), C-24 ( $\delta_C$  129.3), C-25 ( $\delta_C$  132.0), and from H-1' ( $\delta_H$  5.40) to C-23 ( $\delta_C$  75.2) demonstrated the presence of  $\beta$ -D-allopyranosyl function at C-23; 3) the HMBC correlation from the signal of H<sub>3</sub>-28 ( $\delta_H$  1.36) and H<sub>3</sub>-29 ( $\delta_H$  0.88) to C-3 ( $\delta_C$  76.3) revealed that there existed a hydroxy group at C-3. Therefore, compound **3** was assigned as 5 $\beta$ ,19-epoxycucurbita-6,24-dien-3 $\beta$ ,23-diol 23-O- $\beta$ -D-allopyranoside (karaviloside XIII).

Compound **4** was obtained as white powder. It exhibited a  $[\text{M}]^+$  ion at  $m/z$  486.3715 (calcd 486.3709) in the HREIMS, compatible with the molecular formula of  $\text{C}_{31}\text{H}_{50}\text{O}_4$ . The IR spectrum showed characteristic absorptions for hydroxy group (3440  $\text{cm}^{-1}$ ), aldehyde group (1710  $\text{cm}^{-1}$ ) and double



bonds ( $1631\text{ cm}^{-1}$ ). The 1D-NMR spectra of **4** revealed seven methyls [including a secondary methyl ( $\delta_{\text{H}}$  1.10, 3H, d,  $J = 6.4\text{ Hz}$ )], a methoxyl [ $\delta_{\text{H}}$  3.29 (3H, s),  $\delta_{\text{C}}$  (56.0, q)], two trisubstituted double bond [ $\delta_{\text{C}}$  146.1 (s), 124.7 (d), 128.3 (d), 135.0 (s)] and an aldehyde carbon at  $\delta_{\text{C}}$  208.4 (d). These suggested that the 1D-NMR data of **4** were similar to those of momordicine I [28] except that the hydroxy group at C-23 in momordicine I was replaced by a methoxyl group in **4**, which was established by the carbon signal at C-23 in which **4** was shifted downfield to  $\delta$  75.1 ( $\Delta\delta$  8.5) by comparison with that of in momordicine I. Furthermore,  $\beta$ -orientation of 7-OH, 3-OH, and 19-CHO were carried out by ROESY correlations of H-3/H<sub>3</sub>-28, H-7/H<sub>3</sub>-30, H-19/H-1, and H-19/H-8. The above evidence established that **4** possesses the structure 3 $\beta$ ,7 $\beta$ -dihydroxy-23-methoxycucurbita-5,24-dien-19-al (momordicine VI).

Compound **5** was isolated as white powder, and was analyzed for molecular formula  $\text{C}_{34}\text{H}_{52}\text{O}_7$  based on its HREIMS ( $m/z$ , 572.3703  $[\text{M}]^+$ , calcd 572.3713). The IR spectrum displayed diagnostic absorptions at hydroxy group ( $3440\text{ cm}^{-1}$ ), ester ( $1728\text{ cm}^{-1}$ ) and trans double bands ( $1629$  and  $977\text{ cm}^{-1}$ ). The 1D-NMR spectra of **5** exhibited the presence of seven methyls (including a secondary methyl), an oxymethyl, two di- and trisubstituted double bonds, two esterified carbons and an aldehyde carbon. Detailed analysis of the  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR data associated with HSQC and HMBC spectra suggested that compound **5** was similar to 3 $\beta$ ,7 $\beta$ ,25-trihydroxycucurbita-5,(23 $E$ )-dien-19-al [26] except that the hydroxy group at C-3 in the above known compound was replaced by the  $-\text{OCOCH}_2\text{COOCH}_3$  fragment in **5**. The HMBC correlations of H-2'' ( $\delta_{\text{H}}$  3.59, 3.60) with C-1'' ( $\delta_{\text{C}}$  168.0) and C-3'' ( $\delta_{\text{C}}$  166.9), and of OMe-1'' ( $\delta_{\text{H}}$  3.68) with C-1'' ( $\delta_{\text{C}}$  168.0) confirmed the presence of  $-\text{OCOCH}_2\text{COOCH}_3$  fragment, and the HMBC correlations of H-3 ( $\delta_{\text{H}}$  5.02) to C-3'' ( $\delta_{\text{C}}$  166.9), C-4, Me-28, and Me-29 further suggested that the fragment was connected to C-3. The correlations of H-3/H<sub>3</sub>-28, H-7/H<sub>3</sub>-30, H-19/H-1, and H-19/H-8 were observed in the ROESY experiments of **5**, suggesting 3-OH, 7-OH and C-19 as  $\beta$ -oriented. Thus, compound **5** was elucidated as 3 $\beta$ ,7 $\beta$ ,25-trihydroxycucurbita-5, 23( $E$ )-dien-19-al 3-propanedioic acid, monomethyl ester (momordicine VII).

Compound **6**, a white powder, was determined as  $\text{C}_{35}\text{H}_{54}\text{O}_7$  from its HREIMS  $m/z$  586.3862,  $[\text{M}]^+$ , calcd 586.3870). Comparison of the 1D-NMR spectroscopic data of **6** with those of **5** (Tables 1 and 2) indicated strong resemblance in all signal except that the C-23, C-24, and C-25 signals in the spectra of **6** were shifted downfield to  $\delta_{\text{C}}$  128.1 ( $\Delta\delta$  3.5) and 74.7 ( $\Delta\delta$  4.6) and upfield to  $\delta_{\text{C}}$  136.7 ( $\Delta\delta$  3.5), respectively, which suggested that the extra methoxyl group was revealed at C-25. And this was confirmed by the HMBC correlations of 25-OMe ( $\delta_{\text{H}}$  3.10) and C-25 ( $\delta_{\text{C}}$  74.7, s). The ROESY spectrum showed that compounds **6** and **5** possessed the similar configurations. Furthermore, in the  $^1\text{H}$  NMR spectra, H-23 at  $\delta_{\text{H}}$  5.45 (1H, dd,  $J = 6.6, 14.4\text{ Hz}$ ) and H-24 at  $\delta_{\text{H}}$  5.35 (1H, d,  $J = 15.7\text{ Hz}$ ) confirmed that the configuration of  $\Delta^{23}$  was  $E$ . Thus, compound **6** was established to be 3 $\beta$ ,7 $\beta$ -dihydroxy-25-methoxycucurbita-5,23( $E$ )-dien-19-al-3-propanedioic acid, monomethyl ester (momordicine VIII).

The cytotoxic activities of compounds **3**, **4** and **6** were evaluated against five human cancer cell lines (HL-60, SMMC-7721, A-549, MCF-7, and SW480). Compounds **3** and **4** showed all the  $\text{IC}_{50} > 40.0\text{ }\mu\text{mol/L}$ ; compound **6** exhibited a weak

cytotoxic effect against all the above five cell lines with the  $\text{IC}_{50}$  values at 16.2, 20.3, 20.5, 16.9, and  $14.3\text{ }\mu\text{mol/L}$ , respectively.

## Acknowledgments

The project was financially supported by the General Program of Natural Science Foundation of China (NSFC No. 81373288) and the Cooperation Program between Guangdong and CAS (1312224900009[2013], 2009B091300135), Knowledge Innovation Program of the CAS (Grant No. KSZD-EW-Z-004-01), as well as Foundation of State Key Laboratory of Phytochemistry and Plant Resources in West China (P2010-ZZ14).

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.fitote.2014.03.005>.

## References

- [1] Jiangsu New Medical College. Dictionary of traditional Chinese medicine. Shanghai: Shanghai Science and Technology Publishing House; 1985 1281.
- [2] Lin KW, Yang SC, Lin CN. Antioxidant constituents from the stems and fruits of *Momordica charantia*. Food Chem 2011;127:609–14.
- [3] Liu JQ, Chen JC, Wang CF, Qiu MH. One new cucurbitane triterpenoid from the fruits of *Momordica charantia*. Eur J Chem 2010;1:294–6.
- [4] Cheng BH, Chen JC, Liu JQ, Zhou L, Qiu MH. Cucurbitane-type triterpenoids from *Momordica charantia*. Helv Chim Acta 2013;96:1111–20.
- [5] Begum S, Ahmed M, Siddiqui BS, Khan A, Saifi ZS, Arif M. Triterpenes, a sterol and a monocyclic alcohol from *Momordica charantia*. phytochemistry 1997;44:1313–20.
- [6] El-Gengaihi S, Karawya MS, Selim MA, Motawe HM, Ibrahim N, Faddah LM. A novel pyrimidine glycoside from *Momordica charantia* L. Pharmazie 1995;50:361–2.
- [7] Harinantenaina L, Tanaka M, Takaoka S, Oda M, Mogami O, Uchida M, et al. *Momordica charantia* constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull 2006;54:1017–21.
- [8] Tan MJ, Ye JM, Turner N, Cordula HB, Ke CQ, Tang CP, et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 2008;15:263–73.
- [9] Keller AC, Ma J, Kavalier A, He K, Brillantes AB, Kennelly EJ. Saponins from the traditional medicinal plant *Momordica charantia* stimulate insulin secretion in vitro. Phytomedicine 2011;19:32–7.
- [10] Akihisa T, Higo N, Tokuda H, Ukiya M, Akazawa H, Tochigi Y, et al. Cucurbitane-type triterpenoids from the fruits of *Momordica charantia* and their cancer chemopreventive effects. J Nat Prod 2007;70:1233–9.
- [11] Pitchakarn P, Ogawa K, Suzuki S, Takahashi S, Asamoto M, Chewonarin T, et al. *Momordica charantia* leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci 2010;101:2234–40.
- [12] Pitchakarn P, Suzuki S, Ogawa K, Pompimon W, Takahashi S, Asamoto M, et al. Induction of G1 arrest and apoptosis in androgen-*Momordica charantia* (bitter melon) reduces obesity-associated macrophage and mast cell infiltration as well as inflammatory cytokine expression in adipose tissues dependent human prostate cancer by Kuguacin J, a triterpenoid from *Momordica charantia* leaf. Cancer Lett 2011;306:142–50.
- [13] Liu CH, Yen MH, Tsang SF, Gan KH, Hsu HY, Lin CN. Antioxidant triterpenoids from the stems of *Momordica charantia*. Food Chem 2010;118:751–6.
- [14] Yasui H, Kato A, Yazawa M. Antifeedants to armyworms, *Spodoptera litura* and *Pseudaletia separata*, from bitter gourd leaves, *Momordica charantia*. J Chem Ecol 1998;24:803–13.
- [15] Hasani-Ranjbar S, Nayeibi N, Larjani B, Abdollahi M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol 2009;15:3073–85.
- [16] Bao B, Chen YG, Zhang L, Na Xu YL, Wang X, Liu J, et al. *Momordica charantia* (bitter melon) reduces obesity-associated macrophage and mast cell infiltration as well as inflammatory cytokine expression in adipose tissues. PLoS One 2013;8:e84075.

- [17] Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (*Momordica charantia*) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. *Cancer Res* 2010;70:1925–31.
- [18] Battelli MG, Polito L, Bolognesi A, Lafleur L, Fradet Y, Stirpe F. Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. *Int J Cancer* 1996;65:485–90.
- [19] Kimura Y, Akihisa T, Yuasa N, Ukiya M, Suzuki T, Toriyama M, et al. Cucurbitane-type triterpenoids from the fruit of *Momordica charantia*. *J Nat Prod* 2005;68:807–9.
- [20] Frelek J, Klimek A, Ruskowska P. Dinuclear transition metal complexes as auxiliary chromophores in chiroptical studies on bioactive compounds. *Curr Org Chem* 2003;7:1081–104.
- [21] Di Bari L, Pescitelli G, Pratelli C, Pini D, Salvadori P. Determination of absolute configuration of acyclic 1,2-diols with  $\text{Mo}_2(\text{OAc})_4$ . 1. Snatzke's method revisited. *J Org Chem* 2001;66:4819–25.
- [22] Frelek J, Ruskowska P, Suszczynska A, Szewczyk K, Osuch A, Jarosz S, et al. Configurational assignment of sugar erythro-1,2-diols from their electronic circular dichroism spectra with dimolybdenum tetraacetate. *Tetrahedron Asymmetry* 2008;19:1709–13.
- [23] Gorecki M, Jablonska E, Kruszezwska A, Suszczynska A, Urbanczyk-Lipkowska Z, Gerards M, et al. Practical method for the absolute configuration assignment of tert/tert 1,2-diols using their complexes with  $\text{Mo}_2(\text{OAc})_4$ . *J Org Chem* 2007;72:2906–16.
- [24] Liu J, Du D, Si YK, Lü HN, Wu XF, Li Y, et al. Application of dimolybdenum reagent  $\text{Mo}_2(\text{OAc})_4$  for determination of the absolute configurations of vic-diols. *Chin J Org Chem* 2010;30:1270–8.
- [25] Mulholland DA, Sewram V, Osborne R, Pegel KH, Connolly JD. Cucurbitane triterpenoids from the leaves of *Momordica charantia*. *Phytochemistry* 1997;42:391–5.
- [26] Fatope MO, Takeda Y, Yamashita H, Okabe H, Yamauchi T. New cucurbitane triterpenoids from *Momordica charantia*. *J Nat Prod* 1990;53:1491–7.
- [27] Matsuda H, Nakamura S, Murakami T, Yoshikawa M. Structures of new cucurbitane-type triterpenes and glycosides, karavilagenins D and E, and karavilosides VI, VII, VIII, IX, X, and XI, from the fruit of *Momordica charantia*. *Heterocycles* 2007;71:331–41.
- [28] Yasuda M, Iwamoto M, Okabe H, Yamauchi T. Structures of momordicines I, II and III, the bitter principles in the leaves and vines of *Momordica charantia* L. *Chem Pharm Bull* 1984;32:2044–7.